D
David Khayat
Researcher at University of Paris
Publications - 12
Citations - 4955
David Khayat is an academic researcher from University of Paris. The author has contributed to research in topics: Cancer & DNA methylation. The author has an hindex of 8, co-authored 12 publications receiving 4777 citations. Previous affiliations of David Khayat include Rhône-Poulenc.
Papers
More filters
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Journal ArticleDOI
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Ayalew Tefferi,Hagop M. Kantarjian,S. Vincent Rajkumar,Larry Baker,J L Abkowitz,John W. Adamson,Ranjana H. Advani,James P. Allison,Karen H. Antman,Robert C. Bast,John M. Bennett,Edward J. Benz,Nancy Berliner,Joseph R. Bertino,Ravi Bhatia,Smita Bhatia,Deepa Bhojwani,Charles D. Blanke,Clara D. Bloomfield,Linda D. Bosserman,Hal E. Broxmeyer,John C. Byrd,Fernando Cabanillas,George P. Canellos,Bruce A. Chabner,Asher Chanan-Khan,Bruce D. Cheson,Bayard D. Clarkson,Susan L. Cohn,Gerardo Colon-Otero,Jorge E. Cortes,Steven Coutre,Massimo Cristofanilli,Walter J. Curran,George Q. Daley,Daniel J. DeAngelo,H. Joachim Deeg,H. Joachim Deeg,Lawrence H. Einhorn,Harry P. Erba,Francisco J. Esteva,Elihu H. Estey,Isaiah J. Fidler,James M. Foran,Stephen J. Forman,Emil J. Freireich,Charles S. Fuchs,James N. George,Morie A. Gertz,Sergio Giralt,Harvey M. Golomb,Peter L. Greenberg,Jordan U. Gutterman,Robert I. Handin,Samuel Hellman,Paulo M. Hoff,Ronald Hoffman,Waun Ki Hong,Mary M. Horowitz,Gabriel N. Hortobagyi,Clifford A. Hudis,Jean Pierre J. Issa,Bruce E. Johnson,Philip W. Kantoff,Kenneth Kaushansky,David Khayat,Fadlo R. Khuri,Thomas J. Kipps,Margaret L. Kripke,Robert A. Kyle,Richard A. Larson,Theodore S. Lawrence,Ross L. Levine,Michael P. Link,Scott M. Lippman,Sagar Lonial,Gary H. Lyman,Gary H. Lyman,Maurie Markman,John Mendelsohn,Neal J. Meropol,Yoav H. Messinger,Therese M. Mulvey,Susan O'Brien,Roman Perez-Soler,Raphael E. Pollock,Josef T. Prchal,Oliver W. Press,Jerald P. Radich,Kanti R. Rai,Saul A. Rosenberg,Jacob M. Rowe,Hope S. Rugo,Carolyn D. Runowicz,Brenda M. Sandmaier,Alan Saven,Andrew I. Schafer,Charles A. Schiffer,Mikkael A. Sekeres,Richard T. Silver,Lillian L. Siu,David P. Steensma,F. Marc Stewart,Wendy Stock,Richard Stone,Rainer Storb,Louise C. Strong,Martin S. Tallman,Michael A. Thompson,Naoto T. Ueno,Richard A. Van Etten,Julie M. Vose,Peter H. Wiernik,Eric P. Winer,Anas Younes,Andrew D. Zelenetz,Charles A. Lemaistre +116 more
TL;DR: Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H; Abkowitz, Jan L; Adamson, John W; Advani, Ranjana Hira; Antman, Karen H;Antman, John C; Bennett, John M; Benz, Edward J; Berliner, Nancy; Bertino, Joseph; Bhatia, Ravi; Bhattacharya, Smita; Bhojwani, Deepa; Blanke, Charles D; Bloomfield, Clara
Journal ArticleDOI
Pancreatic cancer treatment and research: an international expert panel discussion
Margaret A. Tempero,Jordan Berlin,Michel Ducreux,Daniel G. Haller,Peter Harper,David Khayat,H.-J. Schmoll,Alberto Sobrero,E. Van Cutsem +8 more
TL;DR: Progress in research combined with encouraging improvements from the past offer hope for the future of pancreatic cancer patients.
Journal ArticleDOI
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
TL;DR: Among biological predictors, some studies indicate that activated EGFR, EGFR amplification, absence of KRAS mutations, PTEN expression, and low VEGFR expression are implicated in response to anti-EGFR monoclonal antibodies.
Journal ArticleDOI
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.
Gabriel G. Malouf,Ronan Flippot,Yiyu Dong,Renzo G. DiNatale,Ying-Bei Chen,Xiaoping Su,Eva Compérat,Morgan Rouprêt,Roy Mano,Kyle A. Blum,Hui Yao,Roger Mouawad,Jean Philippe Spano,David Khayat,Jose A. Karam,Thai H. Ho,Satish K. Tickoo,Paul Russo,James J. Hsieh,Nizar M. Tannir,A. Ari Hakimi +20 more
TL;DR: It is shown that Hippo pathway alterations are a feature of sRCC, and enable the exploration of the Hippo pathways as a novel potential therapeutic target.